MAPT and Cognitive impairment: Most studies promisingly signify a general trend of positive dose-dependent effects of RJ on the pathologies underlying cognitive impairments (e.g., oxidative stress, neuroinflammation, and Aβ and tau pathology) [28,70,92,95,115,116,119] in vitro and in vivo, despite the large heterogeneity in cell lines and species that were used as models of AD or cognitive aging, as well as variations in RJ preparation (e.g., enzyme treatment, lyophilization, etc.), dose, and route of administration (oral, gavage, or subcutaneous) across the available literature.